Pages that link to "Q36615986"
Jump to navigation
Jump to search
The following pages link to Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. (Q36615986):
Displaying 50 items.
- Mutations in GNA11 in uveal melanoma (Q24625723) (← links)
- Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi (Q24646052) (← links)
- Oncogenic mutations in GNAQ occur early in uveal melanoma (Q24658558) (← links)
- Drosophila as a Potential Model for Ocular Tumors (Q26750375) (← links)
- Metastatic uveal melanoma: biology and emerging treatments (Q27028063) (← links)
- Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype (Q27334924) (← links)
- The genetics of uveal melanoma: current insights (Q28073150) (← links)
- Uveal Melanoma: Current Trends in Diagnosis and Management (Q28073924) (← links)
- Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT). (Q30384829) (← links)
- In-vivo xenograft murine human uveal melanoma model develops hepatic micrometastases (Q33597703) (← links)
- A molecular revolution in uveal melanoma: implications for patient care and targeted therapy (Q33717375) (← links)
- Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. (Q33819083) (← links)
- Uveal melanoma cell growth is inhibited by aminoimidazole carboxamide ribonucleotide (AICAR) partially through activation of AMP-dependent kinase (Q33872396) (← links)
- The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells (Q34096861) (← links)
- The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma (Q34130528) (← links)
- The genetics of uveal melanoma: an emerging framework for targeted therapy (Q34249080) (← links)
- Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance (Q34272199) (← links)
- Oncogenic GNAQ and GNA11 mutations in uveal melanoma in Chinese (Q34287626) (← links)
- High throughput mass spectrometry-based mutation profiling of primary uveal melanoma (Q34414476) (← links)
- Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512. (Q34504963) (← links)
- Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma (Q34633455) (← links)
- Ocular melanoma: an overview of the current status (Q34653896) (← links)
- Mechanisms of resistance to imatinib mesylate in KIT-positive metastatic uveal melanoma. (Q34660509) (← links)
- Genomic, prognostic, and cell-signaling advances in uveal melanoma (Q35163192) (← links)
- Combined PKC and MEK inhibition for treating metastatic uveal melanoma (Q35168515) (← links)
- Molecular bases of cutaneous and uveal melanomas (Q35174214) (← links)
- Prognostic parameters for the primary care of melanoma patients: what is really risky in melanoma? (Q35324807) (← links)
- Eye cancer: unique insights into oncogenesis: the Cogan Lecture (Q35585887) (← links)
- Genetic and molecular characterization of uveal melanoma cell lines (Q35783799) (← links)
- Pathway aberrations of murine melanoma cells observed in Paired-End diTag transcriptomes (Q35906375) (← links)
- NF-kappaB activation in melanoma (Q36416479) (← links)
- Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization (Q36468749) (← links)
- M2/M1 ratio of tumor associated macrophages and PPAR-gamma expression in uveal melanomas with class 1 and class 2 molecular profiles (Q36565563) (← links)
- Inflammation in uveal melanoma (Q36615048) (← links)
- Molecular pathology of uveal melanoma (Q36615059) (← links)
- Point mutations of protein kinases and individualised cancer therapy (Q36632245) (← links)
- A Rare Thyroid Metastasis from Uveal Melanoma and Response to Immunotherapy Agents (Q36773500) (← links)
- The T1799A point mutation is present in posterior uveal melanoma (Q36977553) (← links)
- BRAF kinase in melanoma development and progression. (Q37086193) (← links)
- Emerging insights into the molecular pathogenesis of uveal melanoma (Q37298647) (← links)
- Subtoxic Levels of Apigenin Inhibit Expression and Secretion of VEGF by Uveal Melanoma Cells via Suppression of ERK1/2 and PI3K/Akt Pathways (Q37322759) (← links)
- Minimal contribution of ERK1/2-MAPK signalling towards the maintenance of oncogenic GNAQQ209P-driven uveal melanomas in zebrafish (Q37457622) (← links)
- Systemic treatment of metastatic uveal melanoma: review of literature and future perspectives (Q37482566) (← links)
- Liver resection and ablation for metastatic melanoma: A single center experience (Q37518270) (← links)
- Treatment implications of the emerging molecular classification system for melanoma (Q37846978) (← links)
- Modelling melanoma in mice. (Q37943839) (← links)
- Insights into melanoma: targeting the mTOR pathway for therapeutics (Q38012466) (← links)
- A review of advanced genetic testing for clinical prognostication in uveal melanoma (Q38134805) (← links)
- Melanoma mutagenesis and aberrant cell signaling (Q38146707) (← links)
- Metastatic melanoma to the liver: a contemporary and comprehensive review of surgical, systemic, and regional therapeutic options (Q38168469) (← links)